British multinational corporation «GlaxoSmithKline plc» plans to significantly reduce the prices of medicines in developing markets next spring, - reported on Nov. 30 edition of the «Financial Times». The cost of drugs on them can be reduced by 2 / 3 compared with that in developed markets. Hussein Abbas (Abbas Hussain), president of the department to work in developing countries «GlaxoSmithKline», said that in his opinion, it is preferable to establish low-cost medicines in order to receive no income from the 100 units of 100 patients, but lower prices and a 100 [pc] income from 500 patients.
To the remark of some manufacturers that reduce the cost of medicines in emerging markets could lead to parallel importation of medicines in the developed countries and hence their "washout" from emerging markets, A. Hussey noted that studies «GlaxoSmithKline» suggest that it did not significantly affect the income of the company.
Cenforce 100
ReplyDeletecenforce